Nisa Investment Advisors LLC Reduces Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Nisa Investment Advisors LLC cut its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAGet Rating) by 70.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 457 shares of the biotechnology company’s stock after selling 1,077 shares during the period. Nisa Investment Advisors LLC’s holdings in Enanta Pharmaceuticals were worth $33,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Point72 Hong Kong Ltd bought a new position in Enanta Pharmaceuticals in the fourth quarter valued at about $114,000. Soleus Capital Management L.P. lifted its holdings in Enanta Pharmaceuticals by 74.5% in the fourth quarter. Soleus Capital Management L.P. now owns 318,275 shares of the biotechnology company’s stock valued at $23,801,000 after acquiring an additional 135,875 shares during the period. Portland Global Advisors LLC lifted its holdings in Enanta Pharmaceuticals by 21.1% in the fourth quarter. Portland Global Advisors LLC now owns 75,869 shares of the biotechnology company’s stock valued at $5,673,000 after acquiring an additional 13,234 shares during the period. Robeco Institutional Asset Management B.V. bought a new position in Enanta Pharmaceuticals in the fourth quarter valued at about $64,000. Finally, Assenagon Asset Management S.A. lifted its holdings in Enanta Pharmaceuticals by 17.2% in the fourth quarter. Assenagon Asset Management S.A. now owns 111,483 shares of the biotechnology company’s stock valued at $8,337,000 after acquiring an additional 16,334 shares during the period. 98.87% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ENTA has been the topic of several recent research reports. JMP Securities reaffirmed a “buy” rating and issued a $103.00 price objective on shares of Enanta Pharmaceuticals in a research note on Wednesday, June 22nd. Robert W. Baird decreased their price objective on Enanta Pharmaceuticals from $130.00 to $90.00 and set an “outperform” rating on the stock in a research note on Thursday, May 19th. Evercore ISI raised Enanta Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $62.00 price objective on the stock in a research note on Wednesday, July 6th. Roth Capital decreased their price objective on Enanta Pharmaceuticals from $101.00 to $70.00 in a research note on Wednesday, May 11th. Finally, Royal Bank of Canada raised their price objective on Enanta Pharmaceuticals from $64.00 to $67.00 and gave the stock a “sector perform” rating in a research note on Friday, July 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Enanta Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $72.00.

Enanta Pharmaceuticals Trading Up 11.0 %

Shares of ENTA opened at $55.15 on Monday. The company has a market capitalization of $1.14 billion, a PE ratio of -9.99 and a beta of 0.53. The business’s 50 day moving average is $45.55 and its 200 day moving average is $57.65. Enanta Pharmaceuticals, Inc. has a 12-month low of $37.59 and a 12-month high of $102.00.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) last released its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($1.63) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.20). The firm had revenue of $18.72 million for the quarter, compared to analysts’ expectations of $20.40 million. Enanta Pharmaceuticals had a negative net margin of 122.68% and a negative return on equity of 28.80%. During the same quarter in the prior year, the business earned ($1.09) EPS. Equities research analysts predict that Enanta Pharmaceuticals, Inc. will post -5.58 earnings per share for the current year.

Enanta Pharmaceuticals Profile

(Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

See Also

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAGet Rating).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Want More Great Investing Ideas?

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.